The impact of pemafibrate on hypertriglyceridemia in patients with type 2 diabetes: A prospective cohort study.
Phase 4
- Conditions
- dyslipidemi
- Registration Number
- JPRN-UMIN000037385
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 650
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of TG and HDL-C before and after administration of pemafibrate
- Secondary Outcome Measures
Name Time Method 1)total lipid metabolism (remnant, sd-LDL, etc) 2)Liver function 3)Renal function 4)Body weight, Body mass index, Abdominal circumference 5)Fasting plasma glucose, HbA1c, insulin sensitivity and insulin secretion 6)Blood pressure 7)Adverse event 8)Influencing factors on lipid metabolism, liver/renal function, and glucose metabolism 9)Variation of blood and urinary examination including lipid metabolism, as well as abdominal ultrasound findings between pemafibrate group and control